Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
Idebenone for primary progressive multiple sclerosis
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
4-aminopyridine toxicity: a case report and review of the literature.
Remyelination therapy goes to trial for multiple sclerosis

Pages